HOME > ORGANIZATION
ORGANIZATION
- JPMA Chief Fires at Proposed 80-90% Generic Share Target
May 27, 2015
- JPMA Official Praises Sakigake System as “Ground-Breaking,” Expresses Concern Over Impact of Compassionate Use System
May 12, 2015
- “Stable Supply System” Key for Adopting Generics at Insurance Pharmacies: JGA Survey
May 11, 2015
- JPMA Preparing “Action Guidelines” to Ensure Greater Transparency
April 24, 2015
- Expert Warns against Research-Driven Makers’ Foray into Indian Market
April 22, 2015
- JPMA to Step Up Calls for Biowaivers Using IVIVC
April 21, 2015
- MHLW to Inquire with Drug Makers about Payments to PAFSC Members
April 17, 2015
- Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
- APAC Approves “Good Submission Practice” Guidelines Aimed at Reducing Time to Approval in Asia
April 13, 2015
- JPA Vice President Disagrees with Exclusion of OTC-Like Drugs from Insurance Coverage
April 13, 2015
- JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
- October-December Generic Share Down 1.3 Points from Prior Qtr: JGA
March 27, 2015
- 15 Drug Makers to Jointly Purchase 150,000 Compounds for Compound Libraries Over 5-Year Period Starting in FY2015
March 27, 2015
- 1st Generation Poultices “Just One Example” for Proposal to Scrap Health Coverage for OTC-Like Drugs: Shirakawa
March 26, 2015
- Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015
- JPMA to Begin Operating New Statistical Drug Database in FY2015
March 23, 2015
- JPMA Suspends Hasegawa’s Veep Duties for Another 2 Months over CASE-J
March 20, 2015
- FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
- JPWA Calls on MHLW to Narrow Down Range of Pharmacies Subjected to Medical Fee Cut Rule for Low Price Settlement Rates
March 20, 2015
- Kyokai Kenpo Aims to Increase Generic Usage Rate to 65.1%
March 20, 2015
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…